Welcome to our dedicated page for Cannabix Technol news (Ticker: BLOZF), a resource for investors and traders seeking the latest updates and insights on Cannabix Technol stock.
Cannabix Technologies Inc. develops marijuana and alcohol breath-testing technologies for workplace safety, law enforcement, and other safety-sensitive settings. Company news centers on the Marijuana Breath Test, or MBT, including its Breath Collection Unit and single-use Breath Cartridges used to collect breath samples for laboratory analysis of recent cannabis use.
Recurring updates include commercial rollout activity, deliveries through authorized resellers, product validation, regulatory and compliance testing for device hardware, and distribution or education efforts with testing-industry partners. News also covers the company’s work with Omega Laboratories on analytical methods for detecting cannabinoids in breath samples using LC-MS-based testing.
Cannabix Technologies Inc. has received a notice of allowance from the Canadian Intellectual Property Office for its cannabis drug detection device patent application, No. 2887841, filed on April 16, 2015. This device aims to assist law enforcement and employers in identifying THC impairment through breath samples. However, a notice of allowance does not equate to a granted patent. The company continues to develop marijuana breathalyzer technology for workplace and law enforcement use, targeting improvements in public safety.
Cannabix Technologies Inc. is advancing its THC Breath Analyzer by commencing beta testing with a private drug testing clinic in the Northwestern United States. The prototype aims to provide a non-invasive method for detecting recent marijuana use, aligning detection with impairment. Current testing methods identify THC for extended periods, complicating impairment assessments. The Clinic, experienced in drug testing technologies, will assist in enhancing the device's functionality.
Beta tests will target machine learning database development and cross-reactivity analysis.
Cannabix Technologies has developed the latest prototype of its Marijuana Breathalyzer, designed to provide law enforcement and employers a means to test for recent THC use. The new device includes enhancements such as a sterilization module and improved breath flow analysis, yielding results in under five minutes. With growing legalization in the U.S., this innovative technology aims to address the challenges of current drug testing methods that fail to accurately identify impairment. Cannabix's breathalyzer targets immediate use detection, differentiating it from traditional tests.
Cannabix Technologies (CSE: BLO, OTC PINK: BLOZF) has announced significant advancements in its marijuana breathalyzer development. The company achieved enhanced resolving power and molecular specificity with the Cannabix FAIMS Beta 3.2 circuit, utilizing new PCB design and mosfet chip technology. Additionally, a more compact circuit board design improves device portability. The technology isolates and detects THC in breath, aiming for accurate impairment detection, especially in driving. CEO Rav Mlait emphasized the technological progress made despite COVID-19 challenges.